

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO. FILING DATE		ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/438,104	09/438,104 11/10/1999		ASGEIR SAEBO	CONLINCO-040	8881	
23535	7590	05/09/2002				
MEDLEN &		•	EXAMINER			
101 HOWAR SUITE 350	D STRE	ET		JONES, DWAYNE C		
SAN FRANCISCO, CA 94105		A 94105		ART UNIT	PAPER NUMBER	
				1614		
			DATE MAILED: 05/09/2002			

Please find below and/or attached an Office communication concerning this application or proceeding.

<u>F</u>		Applicatio	nN.	Applicant(s)					
•	. —	09/438,104	4	SAEBO ET AL.					
	Office Action Summary	Examiner	-	Art Unit					
	-	Dwayne C	Jones	1614					
	The MAILING DATE of this communication ap			orrespondence address					
Period for Reply									
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM- THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).									
Status	December 4 and a second section (a) filed on 4 ha	·		1					
1)	Responsive to communication(s) filed on <u>the amendment filed on 23 JAN 2002</u> . This action is FINAL . 2b) This action is non-final.								
2a)□	, —			accoution as to the morits is					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.									
Dispositi	on of Claims								
•	Claim(s) 7-24 is/are pending in the application								
	4a) Of the above claim(s) is/are withdrawn from consideration.								
) Claim(s) is/are allowed.								
	Claim(s) <u>7-24</u> is/are rejected.								
•	Claim(s) is/are objected to.								
•	Claim(s) are subject to restriction and/ on Papers	or election re	equirement.						
	The specification is objected to by the Examin	ner .							
•	Fhe drawing(s) filed on is/are: a)☐ acc	<u> </u>	objected to by the Exa	miner.					
/									
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). 11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.									
	If approved, corrected drawings are required in r	reply to this Off	ice action.						
12) The oath or declaration is objected to by the Examiner.									
Priority under 35 U.S.C. §§ 119 and 120									
13)	Acknowledgment is made of a claim for foreign	ign priority und	der 35 U.S.C. § 119(a)-(d) or (f).					
a)[a) ☐ All b) ☐ Some * c) ☐ None of:								
	1. Certified copies of the priority documents have been received.								
	2. Certified copies of the priority documents have been received in Application No								
Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.									
14)∐ A	14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).								
a) ☐ The translation of the foreign language provisional application has been received. 15)☑ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.									
Attachment(s)									
2) Notic	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s))	· <u>-</u>	y (PTO-413) Paper No(s). <u>9</u> . Patent Application (PTO-152) uation Sheet .					

Application/Control Number: 09/438,104 Page 2

Art Unit: 1614

·ż

DETAILED ACTION

Status of Claims

- 1. Claims 7-24 are pending.
- 2. Claims 7-24 are rejected.

Interview Summary Record

3. In response to the updated search, a new rejection was made over the instant claims. For this reason, the substance of the Interview Summary of April 4, 2002 has been incorporated into the new rejections under 35 USC 112, 2nd Paragraph, see below.

Claim Rejections - 35 USC § 112

- 4. The following is a quotation of the second paragraph of 35 U.S.C. 112:
 The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
- 5. Claim 15 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
- 6. Claim 15 recites the limitation "said ester" in the claim. There is insufficient antecedent basis for this limitation in the claims because independent claim 13 does not recite the limitation of an ester. It is suggested that the dependency of claim 15 changes from claim 13 to claim 14 to obviate this anomaly.

Application/Control Number: 09/438,104 Page 3

Art Unit: 1614

7. Claim 21 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

- 8. Claim 21 recites the limitation "said ester" in the claim. There is insufficient antecedent basis for this limitation in the claims because independent claim 19 does not recite the limitation of an ester. It is suggested that the dependency of claim 21 changes from claim 20 to claim 19 to obviate this anomaly.
- 9. Claim 24 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
- 10. Claim 24 recites the limitation "said ester" in the claim. There is insufficient antecedent basis for this limitation in the claims because independent claim 22 does not recite the limitation of an ester. It is suggested that the dependency of claim 24 changes from claim 22 to claim 23 to obviate this anomaly.

Obviousness-type Double Patenting

11. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225

Application/Control Number: 09/438,104

Art Unit: 1614

USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

- 12. A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).
- 13. Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).
- 14. Claims 7-24 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-16 of U.S. Patent No. 6,015,833. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claims of the isomerized conjugated linoleic acid are embraced and taught by U.S. Patent No. 6,015,833. Moreover, U.S. Patent No. 6,015,833 also teaches of peak areas of the isomerized conjugated linoleic acids.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to D. C. Jones whose telephone number is (703) 308-4634. The examiner can normally be reached on Mondays through Fridays from 8:30 am to 6:00 pm. The examiner can also be reached on alternate Mondays.

Application/Control Number: 09/438,104 Page 5

Art Unit: 1614

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Seidel can be reached on (703) 308-4725. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-

1235.

PRIMARY EKAMINER

Tech. Čtr. 1614 April 26, 2002